In a real-world study of patients with Crohn disease, upadacitinib achieved 52.1% clinical remission at 12 weeks and 42.7% endoscopic remission at 6 months, with no new safety concerns reported.

At current vaccination rates, measles could become endemic in the US again within 21 years; the threat extends to rubella, polio, and diphtheria, the study found.

The increased risk of depression when oral contraceptives were started following childbirth was "instantaneous," researchers wrote, and was ~50% greater than nonuse.

Phenomix will showcase new data on prediction of adverse events to GLP-1 RA therapy, a new obesity sub-phenotype, and approaches to improve surgical outcomes.

Your daily dose of the clinical news you may have missed.

CGM is now standard of care in T1D and evidence is solid for a role in insulin-treated T2D; Thomas Martens, MD, shares thoughts on CGM growth in the next 3-5 years.

New data to be presented at ECO 2025 shows new-onset T2D is linked to increased risk of liver, pancreatic, and bowel cancers, but not endometrial or post-menopausal breast cancer.

Martens, medical director of the International Diabetes Center (IDC) in Minneapolis, highlights an IDC resource that helps target problem areas in management of hyperglycemia.

Northstrive Biosciences received positive FDA feedback for its IND application for EL-22, a probiotic-based treatment for obesity.

While smoking in the US continues to decline, the American Cancer Society reports mixed progress in major cancer risk factors, prevention, and screening.